Cagrilintide
10MG
Cagrilintide supports appetite regulation and satiety pathways to aid weight management and metabolic research.
In stock | ≥99% catalog purity
Description
Product specification
Analytical Profile
Catalog data is presented for material identification and laboratory planning. Batch-specific documentation governs the supplied vial.
| RESEARCH NAME | Cagrilintide |
| FORMAT | Lyophilised powder · 10 mg vial |
| MOLECULAR FORMULA | C194H312N54O59S2 |
| MOLECULAR MASS | 4409 g/mol |
| CAS REGISTRY | 1415456-99-3 |
| ANALYTICAL IDENTITY | HPLC + LC–MS |
| CATALOG CONDITION | Sealed · dry · light-protected |
PROTOCOL LITERACY
Reconstitution Sequence
This source-derived sequence assumes a 10 mg vial and a final reference volume of 1.0 mL. The supplied product documentation remains the controlling instruction.
01
Prepare
Prepare 1.0 mL of bacteriostatic water with sterile equipment.
02
INTRODUCE SLOWLY
Direct the liquid toward the inside wall of the vial to limit foaming.
03
DISSOLVE GENTLY
Roll or swirl with care until the material is dissolved; do not shake.
04
LABEL AND PROTECT
Record the preparation date and keep the vial protected from light.
05
COLD STORAGE
Refrigerate at 2-8°C and use within the four-week reference window.
UNRECONSTITUTED MATERIAL
-20°C
Keep frozen, dry, sealed, and away from direct light. The supplied source describes stability for up to 24 months.
After reconstitution
2-8°C
Keep refrigerated and light-protected. Avoid repeated temperature cycling and follow batch documentation.
Handling principle
ONE THAW
If an approved study protocol requires frozen aliquots, avoid repeated freeze–thaw cycles.
PROTOCOL LITERACY
CAGRILINTIDE DOSAGE CHART
A designed reference covering concentration, weekly schedule models, reconstitution, supply planning, storage, mechanism, study observations, and administration context. It is educational material—not an individualized regimen.
VIAL CONTENT
1.0 MG
+
REFERENCE DILUENT
1.0 MG
=
STOCK CONCENTRATION
1.0 MG/ML
U-100 SCALE
1 Unit = 0.01 ml 100 mcg
01
GRADUAL 8MG MODEL
02
12 MG TRIAL CONTEXT
EDUCATIONAL REFERENCE
GRADUAL 8MG MODEL
| STUDY INTERVAL | STAGE | WEEKLY DOSE | U-100 REFERENCE | SOLUTION VOLUME |
|---|---|---|---|---|
01
WEEKS 1-4 | INITIATION | 2 MG | 20 UNITS | 0.20 ML |
02
WEEKS 5-8 | ESCALATION 01 | 4 MG | 40 UNITS | 0.40 ML |
03
WEEKS 9-12 | INITIATION | 6 MG | 60 UNITS | 0.60 ML |
04
WEEKS 13+ | UPPER REFERENCE | 8 MG | 80 UNITS | 0.80 ML |
01
REFERENCE ASSUMPTIONS
Every unit and volume value shown assumes a 10 mg vial prepared to a total reference volume of 1.0 mL.
02
MATERIAL BOUNDARY
This table does not provide preparation or administration instructions.
03
PROTOCOL CONTROL
Trial documentation and qualified clinical oversight—not this chart—must govern all dosing decisions.
Related products
-
SLU-PP-332
View → This product has multiple variants. The options may be chosen on the product page -
Tirzepatide
View → This product has multiple variants. The options may be chosen on the product page -
Tesamorelin
View → This product has multiple variants. The options may be chosen on the product page -
GLP-1 | GIP | Glucagon
View → This product has multiple variants. The options may be chosen on the product page -
AOD-9604
View → This product has multiple variants. The options may be chosen on the product page -
MOTS-C
View → This product has multiple variants. The options may be chosen on the product page
Product Enquiry
Have a question about this product? Send us your enquiry and our team will get back to you shortly.